
LSTA
Healthcare · Biotechnology · $13.1M market cap
$1.21-0.07 (-5.5%)Nov 13, 4:00 PM EST
Next report
Time not confirmed
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 19, 2026 · upcoming | Time not confirmed | — | — | — |
| Aug 20, 2026 | Time not confirmed | — | -0.54 | — |
| May 7, 2026 | Time not confirmed | — | -0.33 | — |
| Feb 26, 2026 | Time not confirmed | -0.63 | -0.33 | +46.5% |
| Nov 6, 2025 | After the close | -0.53 | -0.49 | +7.5% |
| Aug 7, 2025 | After the close | -0.65 | -0.54 | +16.9% |
| May 8, 2025 | After the close | -0.53 | -0.55 | -3.8% |
| Feb 26, 2025 | After the close | -0.76 | -0.55 | +27.6% |
| Nov 12, 2024 | After the close | -0.75 | -0.59 | +21.3% |
| Aug 12, 2024 | After the close | -0.75 | -0.61 | +18.7% |
| May 9, 2024 | After the close | -0.72 | -0.65 | +9.7% |
| Feb 29, 2024 | After the close | -0.89 | -0.66 | +25.8% |
| Nov 2, 2023 | After the close | -0.93 | -0.65 |
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon…
| +30.1% |
| Aug 14, 2023 | After the close | -0.70 | -0.50 | +28.6% |
| May 9, 2023 | After the close | -0.81 | -0.77 | +4.9% |
| Mar 30, 2023 | After the close | -1.01 | -0.76 | +24.8% |
| Nov 10, 2022 | After the close | -1.27 | -1.47 | -15.7% |
| Aug 4, 2022 | After the close | -1.72 | -1.65 | +4.1% |
| May 5, 2022 | After the close | -1.72 | -1.05 | +39.0% |
| Mar 22, 2022 | After the close | -2.17 | -1.65 | +24.0% |
| Nov 4, 2021 | After the close | -1.95 | -1.80 | +7.7% |
| Aug 5, 2021 | After the close | -2.17 | -1.50 | +30.9% |
| May 6, 2021 | After the close | -1.35 | -2.85 | -111.1% |
| Feb 25, 2021 | After the close | -3.80 | -4.20 | -10.5% |
| Nov 5, 2020 | After the close | -3.37 | -4.35 | -29.1% |
| Aug 13, 2020 | After the close | -5.55 | 7.50 | +235.1% |
| May 7, 2020 | After the close | -4.35 | -5.70 | -31.0% |
| Mar 5, 2020 | After the close | -6.60 | -7.05 | -6.8% |
| Nov 6, 2019 | After the close | -6.45 | -7.05 | -9.3% |
| Aug 8, 2019 | After the close | -6.67 | -7.35 | -10.2% |
| May 9, 2019 | After the close | -6.37 | -6.60 | -3.6% |
| Mar 14, 2019 | After the close | -6.60 | -5.40 | +18.2% |
| Nov 8, 2018 | After the close | -8.10 | -5.40 | +33.3% |
| Aug 9, 2018 | After the close | -9.60 | -6.30 | +34.4% |
| May 10, 2018 | After the close | -10.05 | -7.80 | +22.4% |
| Mar 22, 2018 | After the close | -10.42 | -6.15 | +41.0% |